BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20502274)

  • 1. A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration.
    Togashi Y; Masago K; Mishima M; Fukudo M; Inui K
    J Thorac Oncol; 2010 Jun; 5(6):924-5. PubMed ID: 20502274
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
    Lacouture ME; Hwang C; Marymont MH; Patel J
    J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
    [No Abstract]   [Full Text] [Related]  

  • 4. Exacerbation of radiation fibrosis with erlotinib: another pattern of radiation recall phenomenon.
    Arakawa H; Johkoh T; Sakai F; Kusumoto M; Hataji O; Taguchi O
    Jpn J Radiol; 2011 Oct; 29(8):587-9. PubMed ID: 21928002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palmar bullous blistering induced by erlotinib.
    Berg A; Brustugun OT; Lund-Iversen M; Helland Å
    J Thorac Oncol; 2011 May; 6(5):954. PubMed ID: 21623268
    [No Abstract]   [Full Text] [Related]  

  • 6. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.
    Tsubata Y; Hamada A; Sutani A; Isobe T
    J Cancer Res Ther; 2012; 8(1):154-6. PubMed ID: 22531540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib-associated alopecia in a lung cancer patient.
    Costa DB; Kobayashi S; Schumer ST
    J Thorac Oncol; 2007 Dec; 2(12):1136-8. PubMed ID: 18090591
    [No Abstract]   [Full Text] [Related]  

  • 8. An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
    Toh CK; Lee P; Chowbay B; Goh JW; Mancer K; Tan PH
    Acta Oncol; 2007; 46(2):256-8. PubMed ID: 17453379
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary toxicity associated with erlotinib.
    Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
    Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
    Nanda A; Dias-Santagata DC; Stubbs H; O'Hara CJ; Zaner KS; Lynch TJ; Willers H
    Clin Lung Cancer; 2008 Sep; 9(5):285-7. PubMed ID: 18824451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
    Yalçin S; Dizdar O; Yalçin B; Gököz O
    J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
    [No Abstract]   [Full Text] [Related]  

  • 12. Erlotinib or gefitinib for non-small-cell lung cancer.
    Yusuf SW; Kim P; Durand JB
    N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675910
    [No Abstract]   [Full Text] [Related]  

  • 13. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
    Acharya J; Lyon C; Bottomley DM
    J Am Acad Dermatol; 2009 Jan; 60(1):154-7. PubMed ID: 19103369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.
    Hsieh CH; Chang HT; Lin SC; Chen YJ; Wang LY; Hsieh YP; Chen CA; Chong NS; Lin SL; Chen CY; Shueng PW
    BMC Cancer; 2010 Dec; 10():696. PubMed ID: 21194444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.
    Zhuang H; Yuan Z; Chang JY; Wang J; Pang Q; Zhao L; Wang P
    J Thorac Oncol; 2014 Jun; 9(6):882-5. PubMed ID: 24828665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
    Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
    J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
    [No Abstract]   [Full Text] [Related]  

  • 17. Hand-foot syndrome induced by erlotinib (Tarceva(Ⓡ) ).
    Cho YS; Park J; Kim JI; Nam KH; Yun SK; Kim HU
    Int J Dermatol; 2014 Mar; 53(3):e190-2. PubMed ID: 23675736
    [No Abstract]   [Full Text] [Related]  

  • 18. Erlotinib-associated acute pneumonitis: report of two cases.
    Vahid B; Esmaili A
    Can Respir J; 2007 Apr; 14(3):167-70. PubMed ID: 17464382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
    Gridelli C; Maione P; Galetta D; Rossi A
    J Thorac Oncol; 2007 Jan; 2(1):96-8. PubMed ID: 17410020
    [No Abstract]   [Full Text] [Related]  

  • 20. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
    Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
    J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.